Better With Time: An Economic Assessment of Long-Term Mechanical Circulatory Support in a Population Surviving at Least 1 Year with a Left Ventricular Assist Device
- PMID: 30308249
- DOI: 10.1053/j.semtcvs.2018.09.029
Better With Time: An Economic Assessment of Long-Term Mechanical Circulatory Support in a Population Surviving at Least 1 Year with a Left Ventricular Assist Device
Abstract
This study aims to identify the major components of left ventricular assist device (LVAD)-related costs in a population on long-term mechanical circulatory support to gain insight into opportunities for improvements in quality, safety, and efficiency of care for end-stage heart failure patients. This was a single institution, retrospective cost analysis of patients who received a Heartmate II or HeartWare LVAD between November 2005 and October 2015. Payments for hospitalization for device implantation and subsequent readmissions were represented as the institution's 2015 Medicare reimbursement rate. The incidence, average Medicare reimbursement, and length of stay of readmissions were analyzed for the first year postimplant. A full year of LVAD-related hospitalizations in patients surviving ≥12 months, has a median Medicare reimbursement of $247,208. The most common complications related to ventricular assist devices were gastrointestinal bleeding, driveline infection, stroke, and pump thrombosis. Over 90% of total costs were incurred during the initial hospitalization. Seventy-five percent of first-time readmissions occurred within the first 4 months post discharge. Intensive care unit costs accounted for the single largest cost category during readmissions for all of the 4 most common complications. The trends demonstrated suggest that longer lengths of LVAD support in appropriately selected patients results in progressively decreasing cost-per-month up to 12 months, given the large upfront cost of device implantation and relatively modest additional costs of readmissions. This analysis emphasizes the importance of devices with improved complication profiles and clinical protocols to reduce unnecessary intensive care unit stays to increase the cost effectiveness of long-term ventricular assist device therapy.
Keywords: Destination therapy; LVAD; Mechanical circulatory support.
Copyright © 2018 Elsevier Inc. All rights reserved.
Similar articles
-
Vascular complications associated with percutaneous left ventricular assist device placement: A 10-year US perspective.Catheter Cardiovasc Interv. 2020 Feb;95(2):309-316. doi: 10.1002/ccd.28560. Epub 2019 Oct 22. Catheter Cardiovasc Interv. 2020. PMID: 31638737
-
Present-Day Hospital Readmissions after Left Ventricular Assist Device Implantation: A Large Single-Center Study.Tex Heart Inst J. 2015 Oct 1;42(5):419-29. doi: 10.14503/THIJ-14-4971. eCollection 2015 Oct. Tex Heart Inst J. 2015. PMID: 26504434 Free PMC article.
-
Clinical Impact of Diabetes Mellitus on Short-Term Outcomes andIn-Hospital Mortality of Cardiac Mechanical Support with Left Ventricular Assist Device (LVAD): A Retrospective Study from a National Database.Cardiovasc Revasc Med. 2019 Oct;20(10):883-886. doi: 10.1016/j.carrev.2018.12.011. Epub 2018 Dec 14. Cardiovasc Revasc Med. 2019. PMID: 30578171
-
Less Invasive Surgical Approaches for Left Ventricular Assist Device Implantation.Semin Thorac Cardiovasc Surg. 2018 Spring;30(1):1-6. doi: 10.1053/j.semtcvs.2018.01.002. Epub 2018 Jan 31. Semin Thorac Cardiovasc Surg. 2018. PMID: 29366876 Review.
-
Arrhythmias after left ventricular assist device implantation: Incidence and management.Trends Cardiovasc Med. 2018 Jan;28(1):41-50. doi: 10.1016/j.tcm.2017.07.002. Epub 2017 Jul 10. Trends Cardiovasc Med. 2018. PMID: 28734595 Review.
Cited by
-
Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients.Am J Transplant. 2021 Feb;21(2):657-668. doi: 10.1111/ajt.16245. Epub 2020 Sep 15. Am J Transplant. 2021. PMID: 32777173 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical